LSD GENERAL
Drug
GENZYME CORPORATION
Total Payments
$552,958
Transactions
90
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $154,372 | 23 | 1 |
| 2017 | $398,586 | 67 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $525,000 | 7 | 94.9% |
| Unspecified | $27,849 | 81 | 5.0% |
| Food and Beverage | $108.77 | 2 | 0.0% |
Payments by Type
General
$525,109
9 transactions
Research
$27,849
81 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Lysosomal Storage Disease (LSD) Registry Program | GENZYME CORPORATION | $5,738 | 0 |
| LSD (Lysosomal Storage Disease) Registry Program | GENZYME CORPORATION | $3,200 | 0 |
| Lysosomal Registry | GENZYME CORPORATION | $2,537 | 0 |
| Rare Disease Registry Program | GENZYME CORPORATION | $2,100 | 0 |
| IRB Amendment-site Fee for IRB resubmission prep efforts/LSD Registry Program | GENZYME CORPORATION | $1,700 | 0 |
| LSD (Lysosomal Storage Disease) Rare Disease Registry Program | GENZYME CORPORATION | $1,600 | 0 |
| IRB Amendment, Renewal meeting, 090430 LSD Registry Program | GENZYME CORPORATION | $1,000 | 0 |
| LSD Registry Program, IRB approval | GENZYME CORPORATION | $1,000 | 0 |
| LSD Registry Program | GENZYME CORPORATION | $950.00 | 0 |
| LSD Registry Program, IRB Fee-Annual Continuing Review | GENZYME CORPORATION | $950.00 | 0 |
| Lysosomal Storage Disease Registry Studies | GENZYME CORPORATION | $950.00 | 0 |
| LSD (Lysosomal Storage Disorders) Registry Program IRB Billing | GENZYME CORPORATION | $825.00 | 0 |
| 090430 LSD Registry Program | GENZYME CORPORATION | $750.00 | 0 |
| Lysosomal Storage Disease Registry, Institutional Review Board (IRB) 1617 Continuing Review of Protocol | GENZYME CORPORATION | $750.00 | 0 |
| Lysosomal Storage Disease Registry, Institutional Review Board (IRB) 1718 Continuing Review of Protocol | GENZYME CORPORATION | $750.00 | 0 |
| Lysosomal Storage disease Registry Studies | GENZYME CORPORATION | $675.00 | 0 |
| Lysosomal Storage Disorders including but not limited to Fabry, Gaucher, MPS I And Pompe Diseases | GENZYME CORPORATION | $550.00 | 0 |
| Lysosomal Storage Disorders including but not limited to Fabry, Gaucher, MPS I and Pompe Diseases | GENZYME CORPORATION | $550.00 | 0 |
| IRB Amendment / Genzyme LSD Registry Program | GENZYME CORPORATION | $500.00 | 0 |
| IRB Amendment- Expedited review, 090430 LSD Registry Program | GENZYME CORPORATION | $500.00 | 0 |
Top Doctors Receiving Payments for LSD GENERAL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $552,849 | 88 |
| Maria Descartes | Clinical Genetics (M.D.) | Birmingham, AL | $86.33 | 1 |
| , M.D | Clinical Genetics (M.D.) | New Orleans, LA | $22.44 | 1 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $552,958
Product Information
- Type Drug
- Total Payments $552,958
- Total Doctors 2
- Transactions 90
About LSD GENERAL
LSD GENERAL is a drug associated with $552,958 in payments to 2 healthcare providers, recorded across 90 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2018. In 2018, $154,372 was paid across 23 transactions to 1 doctors.
The most common payment nature for LSD GENERAL is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($525,000, 94.9% of total).
LSD GENERAL is associated with 20 research studies, including "Lysosomal Storage Disease (LSD) Registry Program" ($5,738).